Roche vs Pfizer vs Amgen and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Roche 17.5245, Pfizer 16.583, Amgen 10.365, AstraZeneca 15.993.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Roche, Pfizer, Amgen, AstraZeneca.| Metric | Roche | Pfizer | Amgen | AstraZeneca |
|---|---|---|---|---|
| Market Cap | $386.08B | $167.86B | $253.21B | $287.66B |
| Revenue | $35.05B | $16.58B | $10.37B | $15.99B |
| Cost of Revenue | $9.21B | $4.03B | $2.79B | $4.06B |
| Gross Profit | $25.84B | $12.55B | $7.58B | $11.93B |
| Operating Income | $10.90B | $3.67B | $3.71B | $4.32B |
| Net Income | $7.93B | $3.24B | $3.86B | $3.08B |
| R&D Expense | $8.35B | $3.02B | $2.11B | $3.60B |
| Earnings Per Share | $1.23 | $0.56 | $7.08 | $1.97 |
| Gross Margin | 73.7% | 75.7% | 73.1% | 74.6% |
| Operating Margin | 31.1% | 22.1% | 35.8% | 27.0% |
| Net Profit Margin | 22.6% | 19.6% | 37.3% | 19.2% |
| Free Cash Flow | $6.46B | $4.80B | $3.65B | $3.99B |
| Cumulative Free Cash Flow | $305.80B | $361.51B | $172.83B | $125.21B |
| Operating Cash Flow | $8.28B | $5.38B | $4.24B | $4.66B |
| Cash & Equivalents | $6.13B | $1.82B | $13.19B | $7.92B |